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a b s t r a c t
Expression of adenosine deaminase acting on RNA1 (ADAR1) is driven by alternative promoters. Promoter
PA, activated by interferon (IFN), produces transcripts that encode the inducible p150 ADAR1 protein,
whereas PB speciﬁes the constitutively expressed p110 protein. We show using Stat1 / , Stat2 / and
IRF9 / MEFs that induction of ADAR1 p150 occurs by STAT2- and IRF9-dependent signaling that is
enhanced by, but not obligatorily dependent upon, STAT1. Chromatin immunoprecipitation analysis
demonstrated STAT2 at the PA promoter in IFN-treated Stat1 / cells, whereas IFN-treated wild-type cells
showed both STAT1 and STAT2 bound at PA. By contrast, with human 2fTGH cells and mutants U3A or U6A,
ADAR1 induction by IFN was dependent upon both STAT1 and STAT2. These results suggest that
transcriptional activation of Adar1 by IFN occurs in the absence of STAT1 by a non-canonical STAT2-
dependent pathway in mouse but not human cells.
& 2015 Elsevier Inc. All rights reserved.
Introduction
Adenosine deaminase acting on double-stranded RNA1 (ADAR1) is
an interferon (IFN) inducible A-to-I RNA editing enzyme (Patterson
and Samuel, 1995; Samuel, 2011). Expression of the Adar1 gene is
regulated by multiple promoters (George and Samuel, 1999b; Samuel,
2011; Toth et al., 2006). The synthesis of transcripts encoding the p150
isoform of ADAR1 inducible by IFN is driven by the PA promoter
possessing an interferon-stimulated response element (ISRE) charac-
teristic of type I IFNα⧸β-inducible genes (George et al., 2008; George
and Samuel, 1999b).
Binding of type I IFNs to their cognate cell surface receptor,
which is present on most types of cells, triggers the activation of
Jak-STAT signaling (Stark and Darnell, 2012). In the canonical
IFNα⧸β signaling response, phosphorylation of STAT1 and STAT2
transcription factors leads to their dimerization and association
with transcription factor IRF9 to form the heterotrimeric ISGF3
complex. ISGF3 then translocates to the nucleus and binds DNA at
the ISRE element of type I interferon-stimulated genes (Schindler
et al., 2007; Stark and Darnell, 2012). In the case of type II IFNγ
signaling, STAT2 is dispensable. IFNγ inducible genes possessing
the gamma IFN-activated sequence (GAS) require STAT1 for
transcriptional activation. Upon phosphorylation, STAT1 homodi-
merizes to form GAF that translocates to the nucleus, binds GAS
elements and drives inducible transcription (Borden et al., 2007;
Stark and Darnell, 2012). The importance of STAT1 in IFN signaling
leading to innate and adaptive immune defense responses is
illustrated by the effects of genetic disruption of the Stat1 gene
and by viruses and pathogens that antagonize STAT1 function
(Durbin et al., 1996; Meraz et al., 1996; Randall and Goodbourn,
2008; Samuel, 2001). Viral gene products impair STAT1 function
by causing its degradation, by preventing its activation or by
inhibiting its nuclear translocation (Randall and Goodbourn,
2008; Stark and Darnell, 2012).
ADAR proteins are dsRNA adenosine deaminases and they fulﬁll
multiple functions (Gelinas et al., 2011; Samuel, 2011; Toth et al.,
2006). Among these, ADAR1 is anti-apoptotic and protects cells from
adverse cytotoxic effects following viral infection (Toth et al., 2009;
Ward et al., 2011). The inducible ADAR1 p150 protein is found in both
the cytoplasm and nucleus, whereas the constitutively expressed
ADAR1 p110 and ADAR2 are predominantly if not exclusively nuclear
proteins (Bass, 2002; Samuel, 2011). ADAR1, even though inducible by
IFN (George and Samuel, 1999a; Patterson and Samuel, 1995; Patterson
et al., 1995; Schoggins et al., 2014), suppresses both IFN induction and
IFN action in cell culture and intact animals (Hartner et al., 2009; John
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and Samuel, 2014; Li et al., 2012; Okonski and Samuel, 2013; Rice et al.,
2012; Toth et al., 2009). Genetic disruption of the mouse Adar1 gene
by a strategy in which both p150 and p110 are knocked out leads to
uncontrolled apoptosis and impaired maintenance of stem cells
necessary for proper development of the hematopoietic system,
thereby leading to embryonic lethality (Hartner et al., 2004, 2009;
Wang et al., 2004). The selective knockout of the p150 isoform of
ADAR1, while retaining expression of the constitutive p110 protein,
also results in embryonic lethality (Ward et al., 2011).
Mutations in the human Adar1 gene are associated with two
human diseases, dyschromatosis symmetrica hereditaria and Aicardi–
Goutieres (AG) syndrome (Rice et al., 2012; Zhang et al., 2013).
Mutation of Adar1 in AG syndrome patients (Rice et al., 2012), genetic
knockout of Adar1 in mice (Hartner et al., 2009) and stable knockdown
of ADAR1 protein in cultured human cells (Li et al., 2012) all are
characterized by elevated production of type I IFN and a type I IFN-
stimulated gene expression signature that together likely contributes
to the pathogenesis and diseases seen in mice and humans with
ADAR1 deﬁciency. Therefore, proper control of ADAR1 expression
appears essential for normal physiology, both in mice and humans, in
order to prevent interferonopathies.
We earlier observed that the IFN-induced expression of ADAR1
p150 protein in mouse embryo ﬁbroblast cells is independent of
STAT1 but dependent upon STAT2, the JAK1 kinase and IFNAR
receptor (George et al., 2008). Because the STAT1-independent
phenotype for p150 expression in MEFs was unexpected, and
because of ongoing studies with measles virus which displays
tropism for human cells (Li et al., 2012; Okonski and Samuel, 2013;
Toth et al., 2009), we further examined the requirement for STAT1
in the induction of ADAR1 by type I IFN in human cells as well as
mouse cells. We found that in human 2fTGH cells and derived U3A
and U6A mutant cell lines, the induction of p150 ADAR1 followed
the canonical pathway and both STAT1 and STAT2 were essential,
while in mouse cells STAT2 and IRF9 were sufﬁcient and STAT1
dispensable for ADAR1 induction. However, ADAR1 induction by
IFN in STAT1-sufﬁcient MEFs was greater than in Stat1 / null
mutant MEFs.
Results
Induction of ADAR1 RNA and p150 protein are dependent upon both
STAT1 and STAT2 in human 2fTGH cells
We earlier established by Western immunoblot analysis, using
wild-type and null mutant MEF cells, that induction by type I IFN
of the ADAR1 p150 protein isoform is dependent upon STAT2, JAK1
and IFNAR, but independent of STAT1 in mouse cells (George et al.,
2008). Because ADAR1 plays a role in suppression of dsRNA-
dependent innate immune responses in cultured cells following
infection with measles virus that displays tropism for human cells
(Li et al., 2012; Okonski and Samuel, 2013; Pfaller et al., 2015; Toth
et al., 2009), and because mutation of the human Adar1 gene is
implicated as a cause of Aicardi–Goutieres Syndrome that is
associated with a type I interferon signature (Rice et al., 2012),
we sought to determine the requirements for the STAT1 and STAT2
factors in the induction of p150 ADAR1 by IFN in human cells. The
IFN inducible p150 protein isoform of ADAR1 is encoded by exon
1A-containing transcripts expressed from the inducible PA pro-
moter, both in mouse and in human cells (George and Samuel,
1999b; George et al., 2005; Samuel, 2011).
As shown in Fig. 1, induction of exon 1A-containing Adar1 RNA
transcripts in parental human ﬁbrosarcoma 2fTGH cells by IFNα
was robust and substantially elevated compared to the levels
found in untreated cells as measured by PCR (Fig. 1A). By contrast,
in mutant U3A cells lacking STAT1 protein and mutant U6A cells
lacking STAT2 protein (Fig. 1B), exon 1A RNA levels were low and
comparable to that of untreated cells (Fig. 1A). When mutant U3A
cells complemented to express STAT1 (Fig. 1B) were examined,
these cells (U3A-RH) displayed restored induction by IFN of exon
1A-containing RNA (Fig. 1A). As further controls, the transcript
levels of Adar1 (exon 1B), Adar2 and Gapdh also were measured.
They were comparable between untreated and IFN-treated cells in
parental 2fTGH cells, the mutant U3A and U6A cells, and the U3A-
RH cells (Fig. 1A). Exon 1B-containing Adar1 transcripts are
produced by alternative promoter (PB) usage and alternative exon
1 splicing in human cells and they encode the constitutively
expressed p110 ADAR1 protein (George and Samuel, 1999b;
Samuel, 2011).
When whole cell extracts prepared from IFN-treated and
parallel untreated cells were examined by immunoblot analysis,
IFN treatment did not increase the level of p150 ADAR1 in either
U3A (STAT1 mutant) or U6A (STAT2 mutant) cells compared to the
p150 induction seen in parental 2fTGH cells (Fig. 1B). As a further
control, the level of the constitutively expressed p110 ADAR1
isoform was comparable in all cells, untreated or IFN-treated
(Fig. 1B). Likewise, IFN treatment did not increase the level of
either PKR or ISG15 in either U3A or U6A cells, but both proteins
were induced in parental 2fTGH and U3A-RH cells reconstituted
with STAT1 (data not shown). Thus, in human 2fTGH cells,
induction by IFN of ADAR1 p150 appears to follow the canonical
JAK-STAT signaling pathway and is dependent upon both STAT1
and STAT2 (Fig. 1), unlike the p150 induction observed in mouse
MEF cells that was STAT1 independent (George et al., 2008).
Induction of ADAR1 by IFN does not display an obligate requirement
for STAT1 in Stat1(Δ1-124) / MEFs but is less robust than in STAT1-
sufﬁcient MEFs
The STAT1 independence of mouse ADAR1 p150 protein
expression described earlier (George et al., 2008) was observed
using Stat1 / MEF cells in which the ﬁrst three translated exons
corresponding to amino acids 1 to 124 along with 0.7 kb of
upstream sequence was deleted in the knockout (Meraz et al.,
1996), hereafter designated Stat1(Δ1-124) / . We now addition-
ally have examined the requirement for STAT1 in the induction by
IFN of exon 1A-containing Adar1 RNA in these MEFs. As shown in
Fig. 2, exon 1A-containing Adar1 transcripts were inducible by IFN
in Stat1(Δ1-124) / cells as measured by qPCR (Fig. 2A). However,
in wild-type MEFs that express STAT1, the induction was about
2 to 3-fold greater than in the Stat1(Δ1-124) / mutant MEFs
when normalized to Gapdh transcript levels (Fig. 2A). These
results suggest that the induction by type I IFN of Adar1 is not
dependent upon STAT1, but when STAT1 is present as in wild-type
MEFs, the induction achieved by IFN is elevated over the STAT1-
independent induction seen in Stat1(Δ1-124) / MEFs. Consistent
with earlier observations (George et al., 2008), the p150 protein
likewise was inducible by IFN treatment of Stat1(Δ1-124) / MEFs
as measured by Western blotting (Fig. 2B).
Induction of ADAR1 by interferon occurs in Stat1(Δ221-365) / MEFs
but not in Stat2 / or IRF9 / MEFs
The differing requirement for the STAT1 transcription factor for
induction of ADAR1 observed between mouse cells (Stat1(Δ1-124) /
mutant, Fig. 2) and human cells (U3A mutant, Fig. 1) was unexpected.
We therefore examined an independent Stat1 / knockout generated
by deletion of amino acids 221-365 that results in loss of a portion of
the DNA binding domain of STAT1 (Durbin et al., 1996), hereafter
designated Stat1(Δ221-365) / . As shown in Fig. 3, the IFN inducible
expression of exon 1A-containing RNA transcripts was observed both
with Stat1(Δ221-365) / MEFs and wild-type MEFs, but not with
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Stat2 / MEFs, as measured by PCR (Fig. 3A and B). Likewise, the p150
isoform of ADAR1 protein was inducible by IFN treatment of Stat1
(Δ221-365) / mutant MEFs but not detectably by treatment of
Stat2 / MEFs as revealed by quantitation of Western immunoblots
(Fig. 3C). The levels of Adar1 exon 1B-containing transcripts and
Gapdh RNA were comparable in the three MEFs, both untreated and
IFN-treated (Fig. 3A). While exon 1A-containing transcripts that
encode p150 were inducible in both Stat1 mutants, the Stat1(Δ221-
365) / cells (Fig. 3B) and the Stat1(Δ1-124) / cells (Fig. 2A), a
further enhanced induction was observed with wild-type MEFs that
express STAT1 (Figs. 2A, 3B).
The induction of ADAR1 by type I IFN was also dependent upon
IRF9 in MEFs when measured by either exon 1A-containing RNA
(Fig. 4A and B) or p150 protein (Fig. 4C). By contrast, the level of
p110 protein was comparable in wild-type and IRF9 / MEFs, both
untreated and treated (Fig. 4C). These results suggest that both
STAT2 (Fig. 3) and IRF9 (Fig. 4) are required for induction of ADAR1,
but that in Stat1(Δ221-365) / MEFs (Fig. 3) like in Stat1(Δ1-
124) / MEFs (Fig. 2) the induction of ADAR1 is not dependent in
an obligatory manner on STAT1. Furthermore, the results suggest
that if all three components of the canonical ISGF3 signaling
complex (STAT1, STAT2 and IRF9) are present as in wild-type
MEFs, then the induction of Adar1 achieved by type I IFN is further
elevated over the STAT1-independent induction level seen for
Stat1 / mutant MEF cells.
STAT2 protein binds to the IFN-inducible Adar1 promoter region
in vivo in the absence of STAT1
Our results obtained using mutant MEFs revealed a STAT1
independence, but STAT2 dependence, for the induction by IFN
of Adar1 exon 1A RNA and p150 protein in mouse cells. Further-
more, although Adar1 induction occurred in the absence of STAT1
both in Stat1(Δ1-124) / MEFs and Stat1(Δ221-365) / MEFs, the
induction observed in IFN-treated wild-type MEFs was typically
greater than that seen in the Stat1 / MEFs. This ﬁnding
prompted us to examine, in wild-type and Stat1 / mutant MEFs,
the binding of STAT2 protein to the inducible Adar1 promoter
region which possesses an ISRE element (George et al., 2008;
George and Samuel, 1999a). For this purpose, chromatin immune
precipitation (ChIP) assays were performed. As shown in Fig. 5,
both STAT1 (Fig. 5A) and STAT2 (Fig. 5B) were bound to the Adar1
PA promoter region in wild-type MEFs in an IFN-dependent
manner as anticipated. STAT2 also bound at the Adar1 inducible
promoter in Stat1(Δ221-365) / mutant MEFs in an IFN-
dependent manner, although the IFN-induced STAT2 binding in
the mutant MEFs lacking STAT1 was less than that observed in
wild-type MEFs possessing STAT1 (Fig. 5B). No speciﬁc binding of
either STAT1 or STAT2 was observed to the PA promoter region
with untreated MEFs above the control level without speciﬁc
antibody seen for untreated wild-type or Stat1(Δ221-365) /
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MEFs (Fig. 5A and B). Finally, when ChIP analysis was carried out
with the human 2fTGH cells, binding of STAT2 to the Adar1 PA
promoter region was IFN-dependent and observed only in the
parental 2fTGH cells and not in U3A mutant cells (Fig. 6), con-
sistent with the results showing STAT1 and STAT2 dependence for
induction of the exon 1A RNA and p150 protein analyses (Fig. 1).
Discussion
We report herein that the dependency on STAT1 for induction of
RNA adenosine deaminase ADAR1 by type I IFN differs between
mouse and human cell lines commonly utilized in interferon signal
transduction studies. While the presence of STAT1 enhanced induction
of ADAR1 in mouse cells, STAT1 was not required for IFN-induced
Adar1 transcriptional activation based on analyses of MEFs derived
from two independent Stat1 / knockouts. By contrast, ADAR1
induction in human 2fTGH cells was strictly dependent on the
presence of STAT1. And, in both mouse Stat2 / MEFs and human
U6A mutant cells, ADAR1 induction by type I IFNα was not observed.
We earlier reported that the IFNα-induced expression of the
ADAR1 p150 in Stat1(Δ1-124) / MEFs was independent of the
STAT1 transcription factor (George et al., 2008). However, induction
by IFNα of PKR in the Stat1(Δ1-124) / MEF cells was STAT1-
dependent (Das et al., 2006). Furthermore, induction of both ADAR1
p150 and PKR in MEFs displayed requirements for STAT2, JAK1 and
IFNAR pathway components (George et al., 2008). Subsequently, we
carried out similar studies with human 2fTGH parental and U3A and
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U6A mutant cells respectively lacking STAT1 and STAT2. This was
done because the innate immune response is suppressed by ADAR1
(Hartner et al., 2009) including in measles virus-infected cells (Li et
al., 2012; Toth et al., 2009), because some viruses antagonize STAT1
function (Randall and Goodbourn, 2008), and because some viruses
including measles virus display tropism for human cells (Mateo et
al., 2014). In contrast to the induction of Adar1 exon 1A-containing
RNA and p150 protein seen in Stat1(Δ1-124) / MEFs as well as in
Stat1(Δ221-365) / MEFs by IFNα, the IFN-induced expression of
Adar1 exon 1A RNA and p150 protein were not observed in mutant
human cells lacking either STAT1 (U3A) or STAT2 (U6A). ADAR1
induction was observed both in the parental 2fTGH cells and U3A-
RH cells complemented to express STAT1. These ﬁndings suggest a
species difference between mouse and human in the STAT1 require-
ment for induction of Adar1 by type I IFN.
The transcription factor STAT1 was identiﬁed originally as an
essential factor for the canonical signaling by type I IFNs, functioning
as a component of the heterotrimeric ISGF3 complex (Durbin et al.,
1996; Meraz et al., 1996; Stark and Darnell, 2012). Following receptor
binding of type I IFN, STAT1 and STAT2 are phosphorylated and form
heterodimers that associate with IRF9 to form ISGF3 that translocates
to the nucleus and binds the ISRE element to drive transcription.
STAT1-dependent IFNα induced genes inMEFs include ISG54, GBP1, C3
and IRF1 (Durbin et al., 1996; Meraz et al., 1996; Randall and
Goodbourn, 2008; Samuel, 2001) and PKR (Das et al., 2006). However,
more recent studies have revealed STAT1-independent type I IFN
responses, both in cultured cells and intact animals. Among them are
our earlier ﬁnding, based on the analyses using Stat1(Δ1-124) / and
Stat2 / MEFs, that IFNα induction of p150 is STAT1- independent and
STAT2-dependent (George et al., 2008). This conclusion is also true for
Stat1(Δ221-365) / MEFs as shown herein. Induction of mouse Oas1b
and IRF7 by type I IFNs likewise has been described to be STAT1-
independent. IFNβ induction of the Oas1b gene in Stat1(Δ1-124) /
MEFs is STAT1-independent but STAT2-dependent (Pulit-Penaloza
et al., 2012), and induction of IRF7 following lymphocytic choriome-
ningitis virus (LCMV) infection or IFNα treatment is STAT2- and IRF9-
dependent but independent of STAT1 based on Stat1(Δ1-124) /
knockout (Ousman et al., 2005). LCMV also has been seen to evade
the mouse immune system through a type I IFN-mediated response
that is STAT1-independent but STAT2-dependent (Hahm et al., 2005).
The inducible Adar1 PA promoter region, both mouse and
human, includes an ISRE element (George et al., 2008). ChIP results
established STAT2 binding to PA; the binding of STAT2 was observed
in Stat1 / MEFs following IFNα treatment (Fig. 5). Likewise,
binding of STAT2 to ISRE elements of Oas1b and Irf7 genes was
observed in STAT1-deﬁcient mice following Dengue virus infection
(Perry et al., 2011). STAT2 also bound the promoter region of Oas1b
in Stat1 / MEFs (Pulit-Penaloza et al., 2012). These results,
together with our ﬁnding that Adar1 transcriptional activation
was STAT2 and IRF9 dependent but STAT1-independent in mouse
cells, suggest a role for the STAT2 factor independent of its role as a
subunit of ISGF3. While IRF9 lacks an intrinsic ability to mediate
transcriptional activation, a hybrid IRF9-STAT2 fusion protein with
the trans activation domain (TAD) of STAT2 is a robust stimulator of
ISRE-dependent transcription (Kraus et al., 2003). Possibly, in the
case of Adar1, Oas1b and Irf7 induction by IFN, STAT2 functions with
IRF9 as a STAT2 homodimer in type I IFN-treated Stat1 / MEFs to
activate transcription. Overexpression of STAT2, both in Stat1 /
MEFs and human U3C (STAT1 mutant) cells, was recently described
to produce a STAT1-independent IFNα inducible expression of Oas2
and Iﬁt1 (Blaszczyk et al., 2015).
While the central importance of the canonical JAK-STAT signaling
pathway is well established, additional signaling mechanisms have
been described for IFN signaling including the p38 mitogen-activated
protein kinase pathway and the phosphatidyl inositol 3-kinase signal-
ing pathway (Platanias, 2005). These pathways are independent of
STATs, and since ADAR1 induction by IFN is tightly dependent on
STAT2, they seem unlikely to be operative for ADAR1.
Our ﬁnding that, with human 2fTGH derived mutant cells,
Adar1 induction by IFNα to be strictly dependent upon both STAT1
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type (WT) and Stat1(Δ221-365) / MEFs, using either no antibody () or with antibody
(þ) against STAT1 (A) or STAT2 (B). Both chromatin from untreated () and IFN-treated
(þ) MEF cells were analyzed. DNA isolated from input chromatin was ampliﬁed as a
control. *po0.05 by Student’s t-test.
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Fig. 6. STAT1 and STAT2 bind to the ISRE-containing IFN-inducible Adar1 PA
promoter region in parental 2fTGH but not mutant U3A cells. ChIP analysis was
performed using chromatin prepared from parental 2fTGH and STAT1 (U3A)
mutant cells, using either no antibody () or with antibody (þ) against STAT1
or STAT2 as indicated. Chromatin from untreated () and IFN-treated (þ) cells
were analyzed. DNA isolated from input chromatin was analyzed as a control.
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(U3A) and STAT2 (U6A), whereas two different mouse Stat1 /
knockouts displayed STAT1-independent induction of Adar1 that
was STAT2-dependent, suggests a species difference between
mouse and human cells in the type I IFN signaling response
leading to transcriptional activation of Adar1 expression. That is,
in human cells STAT1 is required in addition to STAT2 to activate
Adar1 inducible transcription, whereas in mouse cells STAT2 is
able to function in the absence of STAT1. However, a potential
contributing factor to the STAT1-dependence for ADAR1 induction
seen in U3A cells may be the low level of STAT2 in U3A observed
by us (Fig. 1B) and others (Lou et al., 2011). Other studies likewise
have suggested a species-speciﬁc activity of STAT2. For example,
the NS5 protein of Dengue virus targets STAT2 for degradation in
species-speciﬁc manner: NS5 binds and mediates the degradation
of STAT2 protein from human cells but not mouse cells (Ashour et
al., 2010). STAT2 also displays a species-speciﬁc effect in simian
virus 5 (SV5) infections. Differences between human and mouse
STAT2 are the determinant of SV5-induced STAT1 degradation
seen in human cells but not in mouse cells (Parisien et al., 2002).
Conceivably, the STAT2 factor is also the determinant of the
species difference in the STAT1 requirement between mouse and
human cells for ADAR1 induction by type I IFNs. Interestingly, the
STAT2 in the mouse (925 aa) is about 10% larger than STAT2 in the
human (850 aa) (Schindler et al., 2007).
In summary, transcriptional activation of the Adar1 gene by
type I IFN displays a different requirement for the STAT1 factor
between human and mouse cells in culture. Why this difference
exists is unclear. The mouse may possess a more stringent
requirement for the ADAR1 p150 protein compared to the human,
and hence the existence of an alternate pathway for Adar1
induction in the event that STAT1 protein function is disrupted
in the mouse due to pathogen infection or other physiologic
stresses. ADAR1 p150 is critically important for normal physiology.
We have shown that embryos of mice genetically disrupted for
ADAR1 p150 expression but retaining constitutive p110 expression
die (Ward et al., 2011), similar to the E11.5-12.0 embryonic
lethality seen following disruption of both p150 and p110 expres-
sion (Hartner et al., 2004; Wang et al., 2004). The embryonic
lethality during mouse development recently has been found to be
rescued to live birth in Adar1:Mavs double mutants, in which IFN
induction in response to double-stranded RNA (dsRNA) is pre-
vented (Mannion et al., 2014). ADAR1 is a feedback suppressor of
IFN production (Hartner et al., 2009; Li et al., 2012; Rice et al.,
2012). ADAR1 deﬁciency leads to enhanced type I IFN production,
both in cultured cells (Li et al., 2012) and mice (Hartner et al.,
2009). Interestingly, in humans the Aicardi–Goutieres Syndrome
(AGS), a rare neurological disorder linked to mutations in the
Adar1 gene leading to the dysfunction of ADAR1 proteins, is
characterized by a type I IFN signature (Livingston et al., 2014;
Rice et al., 2012), providing another example of the critical
importance to normal physiology of proper expression of ADAR1.
Materials and methods
Cells and maintenance
Wild-type (WT) mouse embryo ﬁbroblast (MEF) cells and
Stat1 / (Durbin et al., 1996; Meraz et al., 1996) and Stat2 /
(Park et al., 2000) mutant MEFs were generously provided by
Robert Schreiber (Washington University, St. Louis) and Joan
Durbin (New York University, NYC), and Christopher Schindler
(Columbia University, NY), respectively. These MEFs were main-
tained in DMEM (GIBCO) supplemented with 10% FBS (HyClone),
100 U of penicillin/mL and 100 mg of streptomycin/mL, and 1%
sodium pyruvate. IRF9 / mutant primary MEFs and the
corresponding WT cells (Kimura et al., 1996) were generously
provided by Karen Mossman (McMaster University, Canada). These
cells were cultured using alpha MEM-GlutaMax (GIBCO) supple-
mented with 15% FBS (HyClone), 100 U of penicillin/mL, 100 mg of
streptomycin/mL and 2 mM L-glutamine. Human 2fTGH parental
cells, STAT1 (U3A) and STAT2 (U6A) mutant cells, and U3A cells
reconstituted to express STAT1 (U3A-RH) (John et al., 1991;
McKendry et al., 1991) were generously provided by George Stark
(Cleveland Clinic, Ohio). These cells were maintained in DMEM
supplemented with 10% FBS as well as penicillin and streptomycin
as above and 1 mM sodium pyruvate and 250 μg/mL hygromycin B.
Interferon treatment
Cells seeded in 6-well plates were treated with IFN 24 h after
seeding, or left untreated. Treatment was with IFNαA/D (PBL) at
1000 U/mL for 24 h unless otherwise stated. For ChIP analyses,
human cells were primed with 100 U/mL of human IFNγ (PBL) for
18 h followed by treatment with 1000 U/mL IFNαA/D (PBL) for
30 min (Levy et al., 1990; Ward and Samuel, 2003); mouse cells
were primed with 100 U/mL of mouse IFNγ (PBL) for 18 h followed
by 1000 U/mL of IFNαA/D for 30 min.
Western immunoblot analysis
Whole cell extracts were prepared using high salt lysis buffer
containing a protease inhibitor cocktail (Sigma) and western
analysis carried out as previously described (George et al., 2011;
Taghavi and Samuel, 2012), except that the membranes following
transfer were blocked using 5% w/v BSA in Tris-buffered saline.
Protein concentrations were determined by the Bradford assay
using the BioRad reagent. The primary antibodies used for the
immunoblotting were as follows: human ADAR1, Kin88 #2
(Patterson and Samuel, 1995); mouse ADAR1 (sc 73408 15.8.6),
human STAT1 (sc 592 M-22), mouse STAT1 (sc 346 E-23), human
STAT2 (sc 1668 A-7 and sc 476 C-20) and mouse STAT2 (sc 950
L-20) were all from Santa Cruz Biotechnology; β-actin, mouse
monoclonal antibody (Sigma); and, for tubulin, mouse monoclonal
antibody (Sigma-Aldrich). Protein bands were detected by scan-
ning with Li-Cor Odessey infrared imager system (Li-Cor Bios-
ciences) and quantitated using the Odyssey image processing
software (Version 3.0, LiCor).
RNA isolation and PCR analysis
Isolation and analysis of RNA by PCR was performed essentially
as previously described (McAllister et al., 2012; Toth et al., 2006).
Total RNA was isolated by the TriZol method following the
manufacturer’s recommendations from untreated and IFN-
treated cells grown in 6-well plates. RNAs, dissolved in DEPC-
water, were quantiﬁed by a UV spectrophotometer (Nanodrop)
and stored at 80 1C until used. cDNA was prepared from total
RNA (1.0 μg) by reverse transcription using Superscript II reverse
transcriptase (Invitrogen) and random hexamer primers. cDNA
products were ampliﬁed using Taq polymerase (Roche) according
to the manufacturer’s protocol using gene-speciﬁc forward and
reverse primers; ampliﬁcation products were analyzed by agarose
gel electrophoresis and visualized by ethidium bromide staining.
For qPCR, quantiﬁcation of ADAR1 transcripts relative to GAPDH
was carried out using the iQ SYBR green supermix (Bio-Rad) and a
MyIQ single-color real-time qPCR instrument and software (ver-
sion 1.0, Bio-Rad). The following primer-pairs were used: human
ADAR1 Exon 1A-containing transcripts, forward—Exon 1A plus 170.
50-AATGCCTCGCGGGCGCAATGAATC-30 and reverse—Exon 2 minus
273. 50-TGACTTCCGAGATGCACG-30; human ADAR1 exon 1B tran-
scripts, forward—Exon 1B plus 12. 50-GAGAAGGCTACGTGGTGG-30
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and reverse—Exon 2 minus 273 primer as above; mouse Adar1
Exon 1A-containing transcripts, forward—Exon 1A plus 19. 50-
GTCTCAAGGGTTCAGGGGACCC-30 and reverse—Exon 2 minus 646.
50-CCTCTAGGGAATTCCTGGAT-30; mouse Exon 1B-containing tran-
scripts, forward—Exon 1B Plus 72. 50-TCACGAGTGGGCAGCGTCC-
GAGG-30 and reverse—Exon2 Minus 646 primer as above; human
Adar2 transcripts, forward—50-GTGTAAGCACGCGTTGTACTG-30
and reverse—50-CGTAGTAAGTGGGAGGGAACC-30; human GAPDH,
forward—50-GCCTTCCGTGTCCCCACTG-30 and reverse 50-CGCCTGC
TTCACCACCTTC-30; mouse GAPDH, forward—50-GCCTTCCGTGTTCC
TACCC-30 and reverse—50-TGCCTGCTTCACCACCTTC-30.
Chromatin immune precipitation analysis
Chromatin immunoprecipitation (ChIP) analysis of STAT1 and
STAT2 binding was carried out essentially following the protocol of
Cell Signaling using their ChIP-kit. Brieﬂy, conﬂuent monolayers,
either untreated or IFN-treated, were ﬁxed with formaldehyde
(1%) for 10 min at room temperature (RT). Glycine was then added
to a ﬁnal concentration of 125 mM and incubation continued for
5 min at room temperature (Ward and Samuel, 2003). Fixed cells
were harvested after washing the monolayers 3X with cold PBS,
scrapped into cold PBS, and collected by centrifugation and
suspended in ice-cold buffer A containing DTT, PMSF and protease
inhibitor cocktail (Cell Signaling). Nuclei were pelleted by centri-
fugation and the pellet suspended in nuclear lysis buffer B
containing DTT and then treated with micrococcal nuclease for
15 min at 37 1C followed by sonication. The sonicated sample was
clariﬁed by centrifugation. The fragmented chromosomal DNA
cross-linked to protein was incubated overnight at 4 1C with
antibody against STAT1 (for mouse, E-23X, sc-346X, Santa Cruz
Biotechnology or 9172S of Cell Signaling; for human, E-23X, sc-
346X, Santa Cruz Biotechnology) or antibody against STAT2 (for
mouse, LS-C50070, Lifespan Biosciences; for human L-20X, sc-
950X, Santa Cruz Biotechnology). Antibody-protein-DNA com-
plexes were then recovered using Protein G-conjugated Dyna
beads (Magnetic beads- Life Technologies). After extensive wash-
ing, the cross-linking was reversed and the DNA puriﬁed using a
QIAquick PCR puriﬁcation kit (Qiagen). Analysis of the immuno-
precipitated puriﬁed DNA was by PCR using Taq Polymerase
(Roche) or Real Time qPCR using SYBR green supermix, and
promoter speciﬁc forward and reverse primer pairs. The primers
were as follows: for the mouse ADAR1 PA inducible promoter,
Forward—50-GCGGCCCAGCCCTTATGG-30, and Reverse—50-ACCTG-
TGGGTCCCCTGAAC-30; and, for the human ADAR1 PA promoter,
Forward—50-GACTTGTAACCGGCCTGAAACC-30, and Reverse—50-
GCCTCCGCTACTCCGCACTG-30. PCR products were characterized
by agarose gel electrophoresis when Taq polymerase was used.
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